Related Experiment Video
Updated: Feb 6, 2026
Protein Modifications: Protein Kinases and Phosphatases
Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice
Jaemin Lee1, Junli Liu1, Xudong Feng1
1Division of Endocrinology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Abstract:
The increasing global prevalence of obesity and its associated disorders points to an urgent need for the development of novel and effective therapeutic strategies that induce healthy weight loss. Obesity is characterized by hyperleptinemia and central leptin resistance. In an attempt to identify compounds that could reverse leptin resistance and thus promote weight loss, we analyzed a library of small molecules that have mRNA expression profiles similar to that of celastrol, a naturally occurring compound that we previously identified as a leptin sensitizer. Through this process, we identified another naturally occurring compound, withaferin A, that also acts as a leptin sensitizer. We found that withaferin-A treatment of mice with diet-induced obesity (DIO) resulted in a 20-25% reduction of body weight, while also decreasing obesity-associated abnormalities, including hepatic steatosis. Withaferin-A treatment marginally affected the body weight of ob/ob and db/db mice, both of which are deficient in leptin signaling. In addition, withaferin A, unlike celastrol, has beneficial effects on glucose metabolism that occur independently of its leptin-sensitizing effect. Our results show that the metabolic abnormalities of DIO can be mitigated by sensitizing animals to endogenous leptin, and they indicate that withaferin A is a potential leptin sensitizer with additional antidiabetic actions.
Insights
Withaferin A, a natural compound, effectively reduces body weight and improves metabolic health in obese mice by increasing leptin sensitivity. This offers a promising new therapeutic strategy for obesity and related disorders.
Area of Science:
- Metabolic disease research
- Pharmacology
- Obesity therapeutics
Background:
- Global obesity rates are rising, necessitating new weight loss treatments.
- Obesity involves high leptin levels and resistance to its effects.
- Celastrol was previously identified as a leptin sensitizer.
Purpose of the Study:
- To find compounds that reverse leptin resistance and promote weight loss.
- To investigate withaferin A as a potential leptin sensitizer.
Main Methods:
- Screened small molecules with expression profiles similar to celastrol.
- Treated diet-induced obese (DIO) mice with withaferin A.
- Assessed body weight, hepatic steatosis, and glucose metabolism.
Main Results:
- Withaferin A treatment reduced body weight by 20-25% in DIO mice.
- It improved obesity-associated abnormalities like hepatic steatosis.
- Withaferin A demonstrated beneficial effects on glucose metabolism independent of leptin sensitization.
Conclusions:
- Withaferin A is a potent leptin sensitizer with therapeutic potential for obesity.
- It offers additional benefits for glucose metabolism, suggesting broader antidiabetic applications.
Related Concept Videos
Protein Kinases and Phosphatases
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
Regulated Protein Degradation
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
Co-activators and Co-repressors
Activation Energy
Activation and Inactivation of G Proteins